Company intelligence / Profile preview

Pule Pharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Pule Pharmaceutical is a China-based biopharmaceutical company focused on the development and commercialization of innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in the research of GLP-1 receptor agonists and other metabolic regulators, aiming to provide high-quality and affordable treatment options for patients. Pule Pharmaceutical operates integrated R&D and manufacturing facilities in Zhejiang province to support its growing pipeline of small molecule and peptide-based therapeutics. Their lead programs are currently advancing through various stages of clinical development in the Chinese market.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Pule Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pule Pharmaceutical.

Explore the full profile